MTND6P2

Across TCGA pan-cancer cohorts, MTND6P2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTND6P2 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher MTND6P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTND6P2 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

PAAD, BLCA, and THCA are the cancer types where MTND6P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Tertile	All	0.118	0.468	.012	45	view →
BLCA	DFS	Tertile	All	0.159	0.625	.016	45	view →
THCA	DFS	Tertile	II,III,IV	0.145	0.842	<.001	45	view →
TGCT	DFS	Tertile	All	0.099	0.801	.011	18	view →
PCPG	DFS	Tertile	All	0.161	0.819	.004	18	view →
SARC	DFS	Tertile	All	0.101	0.611	.013	18	view →
SKCM	OS	Tertile	IV	0.133	0.621	.019	9	view →
STAD	DFS	Tertile	IV	0.520	0.250	.033	9	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTND6P2–PAAD (DFS)

Open the PAAD breakdown →